Provided by Tiger Trade Technology Pte. Ltd.

Applied DNA Sciences

5.62
0.0000
Volume:- -
Turnover:- -
Market Cap:7.26M
PE:0.03
High:5.62
Open:5.62
Low:5.62
Close:5.62
52wk High:190.80
52wk Low:2.13
Shares:1.29M
Float Shares:520.00K
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):211.51
EPS(LYR):-1,366.3988
ROE:-137.05%
ROA:-64.06%
PB:1.00
PE(LYR):0.00

Loading ...

Applied DNA Sciences Names Josh Kruger Chairman in Leadership Shift

Reuters
·
Nov 18

Applied DNA Sciences Becomes BNB Plus Corp

Reuters
·
Nov 17

Applied DNA Sciences Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Oct 31

BRIEF-Applied DNA Says On Sept 30 Co Implemented Restructuring Plan - SEC Filing

Reuters
·
Oct 07

Applied DNA Sciences Restructures, Changes Ticker Symbol

TIPRANKS
·
Oct 07

Applied DNA Sciences Inc - on Sept 30, Announces Restructuring Plan - SEC Filing

THOMSON REUTERS
·
Oct 07

Applied DNA Sciences to Change Nasdaq Ticker from APDN to BNBX in October 2025

Reuters
·
Oct 06

Applied DNA Sciences Announces Private Placement Offering

TIPRANKS
·
Oct 01

Top Premarket Decliners

MT Newswires Live
·
Sep 30

Applied DNA announces private placement of up to $58M to start BNB treasury

TIPRANKS
·
Sep 30

Applied DNA Sciences Announces Up to $58 Million Private Placement to Launch BNB-Backed Digital Asset Treasury Strategy

Reuters
·
Sep 30

Applied DNA Sciences Inc - Company to Change Ticker Symbol to 'Bnbx'

THOMSON REUTERS
·
Sep 30

Applied DNA Sciences Inc - Judy Murrah Resigns as President and CEO

THOMSON REUTERS
·
Sep 30

Applied DNA Sciences Announces Private Placement of up to $58 Million to Initiate Bnb Treasury Strategy and Bnb Native Yield Generation

THOMSON REUTERS
·
Sep 30

Applied DNA Sciences Inc. Announces Initiation of Phase I Clinical Trial for CD123-specific CAR-T Cells Using Synthetic LineaDNA™ Technology

Reuters
·
Sep 23

Applied DNA Sciences Q3 EPS $(33.41) Beats $(37.50) Estimate, Sales $304.393K Miss $1.276M Estimate

Benzinga
·
Aug 15

Applied DNA Sciences Reports Q3 2025 Financial Results, Focuses on Synthetic DNA and mRNA Manufacturing Solutions

Reuters
·
Aug 15

Applied DNA Sciences Inc expected to post a loss of $37.50 a share - Earnings Preview

Reuters
·
Aug 08

Applied DNA Sciences Inc expected to post a loss of $37.50 a share - Earnings Preview

Reuters
·
Aug 04

Applied DNA Sciences Secures $600K Follow-On Order for LineaDNA in Cancer Diagnostics

Reuters
·
Jul 24